Institute of Hematology & Blood Diseases Hospital, China: Leukemia, Myeloid, Acute trials

The registry lists 43 Leukemia, Myeloid, Acute studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 28 are open to participants now and 0 have results posted.

Early Phase 1 3Phase 1 14Phase 2 13Phase 3 5No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AMLNot yet recruitingNCT07828535Phase 1
• A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 1
• Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.Not yet recruitingNCT07757672Phase 1/2
• A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT07754799Phase 2
• Plasma ctDNA Monitoring in Pediatric Acute LeukemiaNot yet recruitingNCT07751588
• Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of RelapseNot yet recruitingNCT07686965Phase 3
• Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionNot yet recruitingNCT07644481Not applicable
• A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07441980Phase 1
• VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingNCT07407140Phase 3
• Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AMLRecruitingNCT07304232Phase 2
• Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood TransplantationRecruitingNCT07297576Not applicable
• CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07201727Early Phase 1
• SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesRecruitingNCT07153068Phase 1/2
• Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsRecruitingNCT07132684Phase 3
• MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
• The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCTRecruitingNCT07126782Early Phase 1
• uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesRecruitingNCT07109518Phase 1
• CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesRecruitingNCT07106749Phase 1
• A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06880354Phase 1
• Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingNCT06783790Phase 2
• Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaNot yet recruitingNCT06643195Not applicable
• Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLRecruitingNCT06635681Phase 2
• Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingNCT06613035Phase 3
• VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingNCT06447090Phase 2
• Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06386302Not applicable
• Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid LeukemiaRecruitingNCT05519384Early Phase 1
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaEnrolling by invitationNCT03031249Phase 1/2
• Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive ChemotherapyWithdrawnNCT06770257Phase 2
• Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyTerminatedNCT06449482Phase 1/2
• A Study of c-Kit Mutation as MRD in Acute Myeloid LeukemiaWithdrawnNCT06116318
• Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense ChemotherapyActive, not recruitingNCT06066242Not applicable
• Natural Killer(NK) Cell Therapy in Acute Myeloid LeukemiaCompletedNCT05987696Phase 1
• Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid LeukemiaCompletedNCT05941585Not applicable
• LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaCompletedNCT05739409Not applicable
• CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05654779Phase 1
• Natural Killer(NK) Cell Therapy for Acute Myeloid LeukemiaTerminatedNCT05601466Phase 1
• Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedNCT05361057Phase 2
• Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaActive, not recruitingNCT05356169Phase 2/3
• Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid LeukemiaActive, not recruitingNCT04415008Phase 2
• Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationWithdrawnNCT03560908Phase 1
• The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
• Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid LeukemiaCompletedNCT03165851